Synapse - Hematology-Oncology Fellows

Results (4491)

Phase I/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter's transformation

Meeting Abstract

Mato, A. R.; Svoboda, J.; Prak, E. T. L.; Schuster, S. J.; Tsao, P.; Dorsey, C.; Becker, P. S.; Brander, D. M.; Nasta, S. D.; Landsburg, D. J.; more...
Blood (2018)

Fulltext@MSK | Save

Dependency of spliceosomal mutant MDS on innate immune signaling

Meeting Abstract

Lee, S. C.; North, K.; Chen, C. C.; Kim, E.; Lu, S. X.; Ki, M.; Garippa, R.; Lowe, S. W.; Bradley, R. K.; Abdel-Wahab, O. I.
Blood (2018)

Fulltext@MSK | Save

Therapeutic targeting of an RNA splicing factor network for the treatment of myeloid neoplasms

Meeting Abstract

Lu, S. X.; Wang, E.; Pastore, A.; Xufeng, C.; Imig, J.; Lee, S. C.; Ghebrechristos, Y.; Yoshimi, A.; Bitner, L. E.; Ki, M.; more...
Blood (2018)

Fulltext@MSK | Save

Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial

Meeting Abstract

Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
Blood (2018)

Fulltext@MSK | Save

Homebound autologous hematopoietic cell transplantation for plasma cell disorders in an urban setting is safe for patients and preferred by patients and caregivers

Meeting Abstract

Landau, H. J.; Shah, G. L.; Reeds, M.; Hilden, P.; Andrejko, M.; Applebaum, A.; Batalha, J.; Cazeau, N.; Chung, D. J.; Cortes, M.; more...
Blood (2018)

Fulltext@MSK | Save

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia

Meeting Abstract

King, A. C.; Pappacena, J.; Tallman, M. S.; Park, J. H.; Geyer, M. B.
Blood (2018)

Fulltext@MSK | Save

MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone

Meeting Abstract

Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; more...
Blood (2018)

Fulltext@MSK | Save

Loss of microbiota diversity after autologous stem cell transplant is comparable to injury in allogeneic stem cell transplant

Meeting Abstract

Khan, N.; Peled, J. U.; Gomes, A. L. C.; Devlin, S. M.; Rondon-Clavo, C.; Clurman, A.; Slingerland, J. B.; Slingerland, A. E.; Maloy, M.; Sung, A. D.; more...
Blood (2018)

Fulltext@MSK | Save

TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia

Meeting Abstract

Goldberg, A. D.; Talati, C.; Desai, P.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Sallman, D. A.; Lancet, J. E.; Roboz, G. J.; Sweet, K. L.; more...
Blood (2018)

Fulltext@MSK | Save

Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naive acute lymphoblastic leukemia

Meeting Abstract

Gaulin, C.; Chan, A.; Geyer, M. B.; Park, J. H.; Mantha, S.; Tallman, M. S.
Blood (2018)

Fulltext@MSK | Save